Report

1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.3 STUDY SCOPE 50
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 50
1.3.2 INCLUSIONS AND EXCLUSIONS 51
1.3.3 YEARS CONSIDERED 52
1.4 CURRENCY CONSIDERED 53
1.5 STAKEHOLDERS 53
1.6 SUMMARY OF CHANGES 53
2 RESEARCH METHODOLOGY 55
2.1 RESEARCH DATA 55
2.2 RESEARCH APPROACH 56
2.2.1 SECONDARY DATA 56
2.2.1.1 Key secondary sources 56
2.2.1.2 Key data from secondary sources 57
2.2.1.3 Objectives 57
2.2.2 PRIMARY DATA 58
2.2.2.1 Key primary sources 58
2.2.2.2 Key data from primary sources 59
2.2.2.3 Key industry insights 60
2.2.2.4 Breakdown of primary interviews 61
2.3 MARKET SIZE ESTIMATION 61
2.3.1 BOTTOM-UP APPROACH 62
2.3.1.1 Company revenue estimation approach 62
2.3.1.2 Presentations of companies and primary interviews 63
2.3.1.3 Growth forecast 63
2.3.1.4 CAGR projections 63
2.3.2 TOP-DOWN APPROACH 64
2.4 DATA TRIANGULATION 65
2.5 MARKET SHARE ANALYSIS 65
2.6 RESEARCH ASSUMPTIONS 66
2.6.1 PARAMETRIC ASSUMPTIONS 66
2.6.2 GROWTH RATE ASSUMPTIONS 66
2.7 RESEARCH LIMITATIONS 66
2.8 RISK ASSESSMENT 67
?
3 EXECUTIVE SUMMARY 68
4 PREMIUM INSIGHTS 74
4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW 74
4.2 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 75
4.3 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029 76
4.4 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 76
4.5 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029 77
4.6 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 77
4.7 POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78
5 MARKET OVERVIEW 79
5.1 INTRODUCTION 79
5.2 MARKET DYNAMICS 79
5.2.1 DRIVERS 80
5.2.1.1 Growing incidence of infectious diseases 80
5.2.1.2 Increasing prevalence of chronic diseases 81
5.2.1.3 Favorable government initiatives for point of care testing 83
5.2.1.4 Rising number of waived tests 84
5.2.2 RESTRAINTS 85
5.2.2.1 Pricing pressure on manufacturers 85
5.2.2.2 Stringent regulatory approval process for product commercialization 86
5.2.3 OPPORTUNITIES 86
5.2.3.1 Increasing growth potential in emerging markets 86
5.2.3.2 Rising inclination toward decentralized healthcare system 87
5.2.3.3 Booming healthcare spending worldwide 87
5.2.4 CHALLENGES 88
5.2.4.1 Inadequate standardization with centralized lab methods 88
5.2.4.2 Premium pricing of novel platforms 88
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 89
5.4 PRICING ANALYSIS 90
5.4.1 AVERAGE SELLING PRICE, BY PRODUCT 90
5.4.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER 91
5.4.3 AVERAGE SELLING PRICE, BY REGION 91
5.4.3.1 Average selling price of glucose monitoring test strips, by region 91
5.4.3.2 Average selling price of infectious disease testing products, by region 92
5.4.3.3 Average selling price of cardiometabolic monitoring products, by region 93
5.5 VALUE CHAIN ANALYSIS 94
5.6 SUPPLY CHAIN ANALYSIS 95
5.7 ECOSYSTEM ANALYSIS 96
5.8 INVESTMENT AND FUNDING SCENARIO 98
5.9 TECHNOLOGY ANALYSIS 99
5.9.1 KEY TECHNOLOGIES 99
5.9.1.1 Immunoassays 99
5.9.2 COMPLEMENTARY TECHNOLOGIES 100
5.9.2.1 Molecular diagnostics 100
5.9.3 ADJACENT TECHNOLOGIES 100
5.9.3.1 Biochemical technologies 100
5.10 PATENT ANALYSIS 101
5.11 TRADE ANALYSIS 103
5.11.1 IMPORT DATA FOR HS CODE 3822 103
5.11.2 EXPORT DATA FOR HS CODE 3822 103
5.12 KEY CONFERENCES AND EVENTS, 2025-2026 104
5.13 PORTER'S FIVE FORCES ANALYSIS 105
5.13.1 BARGAINING POWER OF SUPPLIERS 106
5.13.2 BARGAINING POWER OF BUYERS 106
5.13.3 THREAT OF NEW ENTRANTS 106
5.13.4 THREAT OF SUBSTITUTES 106
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 106
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 107
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
5.14.2 KEY BUYING CRITERIA 108
5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET 109
5.15.1 INTRODUCTION 109
5.15.2 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET 109
5.15.3 AI USE CASES 110
5.15.4 KEY COMPANIES IMPLEMENTING AI 111
5.15.5 FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET 112
5.16 REGULATORY LANDSCAPE 112
5.16.1 REGULATORY ANALYSIS 112
5.16.1.1 North America 112
5.16.1.1.1 US 112
5.16.1.1.2 Canada 114
5.16.1.2 Europe 114
5.16.1.2.1 Germany 115
5.16.1.2.2 UK 115
5.16.1.2.3 France 116
5.16.1.2.4 Italy 116
5.16.1.2.5 Spain 116
5.16.1.3 Asia Pacific 117
5.16.1.3.1 China 117
5.16.1.3.2 Japan 117
5.16.1.3.3 India 119
5.16.1.3.4 Australia 119
5.16.1.3.5 South Korea 120
5.16.1.4 Latin America 120
5.16.1.4.1 Brazil 121
5.16.1.4.2 Mexico 121
5.16.1.5 Middle East 122
5.16.1.5.1 Africa 122
5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 122
5.17 CASE STUDY ANALYSIS 124
5.17.1 CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK 124
5.17.2 CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA 125
5.17.3 CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS 125
6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT 126
6.1 INTRODUCTION 127
6.2 GLUCOSE MONITORING PRODUCTS 128
6.2.1 GLUCOSE MONITORING STRIPS 131
6.2.1.1 Growing trend toward preventive healthcare to drive market 131
6.2.2 GLUCOSE MONITORING METERS 134
6.2.2.1 Growing technological advancements in glucose meters to propel market 134
6.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES 137
6.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth 137
6.3 CARDIOMETABOLIC MONITORING PRODUCTS 139
6.3.1 CARDIAC MARKER TESTING PRODUCTS 144
6.3.1.1 Growing government support for cardiovascular diseases to drive market 144
6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 146
6.3.2.1 Need to optimize hospital workflow to favor growth 146
6.3.3 HBA1C TESTING PRODUCTS 149
6.3.3.1 Increasing recommendations by government healthcare authorities to boost market 149
6.4 INFECTIOUS DISEASE TESTING PRODUCTS 151
6.4.1 RESPIRATORY INFECTION TESTING PRODUCTS 154
6.4.1.1 Influenza testing products 156
6.4.1.1.1 Need for targeted treatments to expedite growth 156
6.4.1.2 Tuberculosis 159
6.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth 159
6.4.1.3 Other respiratory infection testing products 162
6.4.2 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 165
6.4.2.1 Growing rate of surgical-site infections to boost market 165
6.4.3 TROPICAL DISEASE TESTING PRODUCTS 168
6.4.3.1 Rising incidence of malaria and dengue to support growth 168
6.4.4 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 171
6.4.4.1 HIV testing products 174
6.4.4.1.1 Growing availability and awareness of testing products to boost market 174
6.4.4.2 Hepatitis testing products 177
6.4.4.2.1 Hepatitis B testing products 180
6.4.4.2.1.1 Increasing prevalence of liver infections to favor growth 180
6.4.4.2.2 Hepatitis C testing products 183
6.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth 183
6.4.4.3 Syphilis testing products 185
6.4.4.3.1 Need for early and accessible diagnosis to expedite growth 185
6.4.4.4 Human papillomavirus testing products 189
6.4.4.4.1 Rising cases of cervical cancer to promote growth 189
6.4.4.5 Chlamydia trachomatis testing products 192
6.4.4.5.1 Growing adoption of advanced techniques to drive market 192
6.4.4.6 Neisseria gonorrhea testing products 195
6.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth 195
6.4.4.7 Herpes simplex virus testing products 197
6.4.4.7.1 Increasing incidence of herpes to support growth 197
6.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 200
6.4.5.1 Rising cases among hospitalized patients to boost demand 200
6.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 202
6.5 COAGULATION MONITORING PRODUCTS 205
6.5.1 PT/INR TESTING PRODUCTS 208
6.5.1.1 Increasing number of atrial fibrillation cases to accelerate growth 208
6.5.2 ACT/APTT TESTING PRODUCTS 210
6.5.2.1 Rise in surgical procedures to speed up growth 210
6.6 PREGNANCY & FERTILITY TESTING PRODUCTS 212
6.6.1 PREGNANCY TESTING PRODUCTS 215
6.6.1.1 Increasing awareness about family planning to stimulate growth 215
6.6.2 FERTILITY TESTING PRODUCTS 218
6.6.2.1 Growing infertility issues to fuel market 218
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS 220
6.7.1 GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET 220
?
6.8 URINALYSIS TESTING PRODUCTS 224
6.8.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH 224
6.9 CHOLESTEROL TESTING PRODUCTS 227
6.9.1 RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH 227
6.10 HEMATOLOGY TESTING PRODUCTS 230
6.10.1 INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH 230
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS 233
6.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET 233
6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS 236
6.12.1 RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH 236
6.13 FECAL OCCULT TESTING PRODUCTS 239
6.13.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET 239
6.14 OTHER PRODUCTS 242
7 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 246
7.1 INTRODUCTION 247
7.2 PRESCRIPTION-BASED TESTING PRODUCTS 247
7.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 247
7.3 OTC TESTING PRODUCTS 251
7.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 251
8 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY 255
8.1 INTRODUCTION 256
8.2 BIOCHEMISTRY 256
8.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH 256
8.3 IMMUNOASSAYS 260
8.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET 260
8.4 MOLECULAR DIAGNOSTICS 264
8.4.1 RT-PCR 267
8.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market 267
8.4.2 INAAT 270
8.4.2.1 Emerging new pathogens to facilitate growth 270
9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE 273
9.1 INTRODUCTION 274
9.2 BLOOD SAMPLES 274
9.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET 274
9.3 NASAL & OROPHARYNGEAL SWABS 278
9.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH 278
9.4 URINE SAMPLES 281
9.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET 281
9.5 OTHER SAMPLES 285
10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER 289
10.1 INTRODUCTION 290
10.2 HOME CARE SETTINGS AND SELF-TESTING 290
10.2.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH 290
10.3 CLINICAL LABORATORIES 293
10.3.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET 293
10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 296
10.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH 296
10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES 299
10.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH 299
10.6 OTHER END USERS 301
11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION 305
11.1 INTRODUCTION 306
11.2 NORTH AMERICA 306
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 316
11.2.2 US 316
11.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth 316
11.2.3 CANADA 323
11.2.3.1 Rising incidence of diabetes and infectious diseases to support growth 323
11.3 EUROPE 331
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 338
11.3.2 GERMANY 339
11.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth 339
11.3.3 FRANCE 346
11.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market 346
11.3.4 UK 352
11.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth 352
11.3.5 ITALY 359
11.3.5.1 Growing burden of infectious and parasitic diseases to boost market 359
?
11.3.6 SPAIN 367
11.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth 367
11.3.7 REST OF EUROPE 373
11.4 ASIA PACIFIC 380
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 388
11.4.2 CHINA 389
11.4.2.1 Increasing impact of diabetes on public health to amplify growth 389
11.4.3 JAPAN 395
11.4.3.1 Booming geriatric population to stimulate growth 395
11.4.4 INDIA 403
11.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth 403
11.4.5 AUSTRALIA 409
11.4.5.1 Growing research investments for next-gen point of care devices to boost market 409
11.4.6 SOUTH KOREA 416
11.4.6.1 Growing focus on innovative diagnostic products to drive market 416
11.4.7 REST OF ASIA PACIFIC 423
11.5 LATIN AMERICA 430
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 437
11.5.2 BRAZIL 438
11.5.2.1 Increasing public initiatives in healthcare to encourage growth 438
11.5.3 MEXICO 444
11.5.3.1 Need for frequent testing for disease management to expedite growth 444
11.5.4 REST OF LATIN AMERICA 451
11.6 MIDDLE EAST & AFRICA 458
11.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET 458
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 464
11.7 GCC COUNTRIES 465
11.7.1 BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH 465
11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 471
12 COMPETITIVE LANDSCAPE 473
12.1 INTRODUCTION 473
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 473
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET 474
12.3 REVENUE ANALYSIS, 2021-2023 475
12.4 MARKET SHARE ANALYSIS, 2023 476
12.5 COMPANY VALUATION AND FINANCIAL METRICS 478
?
12.6 BRAND/PRODUCT COMPARISON 479
12.6.1 ABBOTT 479
12.6.2 F. HOFFMANN-LA ROCHE LTD. 479
12.6.3 NOVA BIOMEDICAL 480
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 480
12.7.1 STARS 480
12.7.2 EMERGING LEADERS 480
12.7.3 PERVASIVE PLAYERS 480
12.7.4 PARTICIPANTS 480
12.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023 482
12.7.5.1 Company footprint 482
12.7.5.2 Region footprint 483
12.7.5.3 Mode of purchase footprint 484
12.7.5.4 Technology footprint 485
12.7.5.5 Sample footprint 486
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 487
12.8.1 PROGRESSIVE COMPANIES 487
12.8.2 RESPONSIVE COMPANIES 487
12.8.3 DYNAMIC COMPANIES 487
12.8.4 STARTING BLOCKS 487
12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 489
12.9.1 DETAILED LIST OF KEY STARTUPS/SMES 489
12.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 489
12.10 COMPETITIVE SCENARIO 490
12.10.1 PRODUCT LAUNCHES AND APPROVALS 490
12.10.2 DEALS 491
13 COMPANY PROFILES 493
13.1 KEY PLAYERS 493
13.1.1 ABBOTT 493
13.1.1.1 Business overview 493
13.1.1.2 Products offered 494
13.1.1.3 Recent developments 497
13.1.1.3.1 Product launches and approvals 497
13.1.1.3.2 Deals 497
13.1.1.4 MnM view 498
13.1.1.4.1 Right to win 498
13.1.1.4.2 Strategic choices 498
13.1.1.4.3 Weaknesses and competitive threats 498
?
13.1.2 SIEMENS HEALTHINEERS AG 499
13.1.2.1 Business overview 499
13.1.2.2 Products offered 500
13.1.2.3 Recent developments 502
13.1.2.3.1 Product launches and approvals 502
13.1.2.3.2 Deals 502
13.1.2.3.3 Expansions 503
13.1.2.4 MnM view 504
13.1.2.4.1 Right to win 504
13.1.2.4.2 Strategic choices 504
13.1.2.4.3 Weaknesses and competitive threats 504
13.1.3 F. HOFFMANN-LA ROCHE LTD 505
13.1.3.1 Business overview 505
13.1.3.2 Products offered 506
13.1.3.3 Recent developments 508
13.1.3.3.1 Product launches and approvals 508
13.1.3.3.2 Deals 508
13.1.3.3.3 Expansions 509
13.1.3.4 MnM view 509
13.1.3.4.1 Right to win 509
13.1.3.4.2 Strategic choices 509
13.1.3.4.3 Weaknesses and competitive threats 510
13.1.4 DANAHER 511
13.1.4.1 Business overview 511
13.1.4.2 Products offered 512
13.1.4.3 Recent developments 514
13.1.4.3.1 Deals 514
13.1.4.4 MnM view 514
13.1.4.4.1 Key strengths 514
13.1.4.4.2 Strategic choices 514
13.1.4.4.3 Weaknesses and competitive threats 515
13.1.5 QUIDELORTHO CORPORATION 516
13.1.5.1 Business overview 516
13.1.5.2 Products offered 517
13.1.5.3 Recent developments 519
13.1.5.3.1 Product launches and approvals 519
13.1.5.3.2 Deals 520
13.1.5.3.3 Expansions 521
13.1.5.4 MnM view 521
13.1.5.4.1 Right to win 521
13.1.5.4.2 Strategic choices 521
13.1.5.4.3 Weaknesses and competitive threats 521
13.1.6 BD 522
13.1.6.1 Business overview 522
13.1.6.2 Products offered 523
13.1.6.3 Recent developments 524
13.1.6.3.1 Deals 524
13.1.6.3.2 Expansions 524
13.1.7 THERMO FISHER SCIENTIFIC INC. 525
13.1.7.1 Business overview 525
13.1.7.2 Products offered 526
13.1.7.3 Recent developments 527
13.1.7.3.1 Product launches and approvals 527
13.1.7.3.2 Deals 527
13.1.8 BIOMERIEUX 528
13.1.8.1 Business overview 528
13.1.8.2 Products offered 529
13.1.8.3 Recent developments 530
13.1.8.3.1 Product launches and approvals 530
13.1.8.3.2 Deals 531
13.1.9 BIOSYNEX SA 532
13.1.9.1 Business overview 532
13.1.9.2 Products offered 533
13.1.9.3 Recent developments 535
13.1.9.3.1 Deals 535
13.1.10 EKF DIAGNOSTICS HOLDINGS PLC 536
13.1.10.1 Business overview 536
13.1.10.2 Products offered 537
13.1.10.3 Recent developments 538
13.1.10.3.1 Product launches and approvals 538
13.1.10.3.2 Deals 538
13.1.10.3.3 Expansions 539
13.1.11 TRINITY BIOTECH 540
13.1.11.1 Business overview 540
13.1.11.2 Products offered 541
13.1.11.3 Recent developments 542
13.1.11.3.1 Product launches and approvals 542
13.1.11.3.2 Deals 542
13.1.12 WERFEN 543
13.1.12.1 Business overview 543
13.1.12.2 Products offered 544
13.1.12.3 Recent developments 545
13.1.12.3.1 Product launches and approvals 545
13.1.12.3.2 Deals 545
13.1.13 NOVA BIOMEDICAL 546
13.1.13.1 Business overview 546
13.1.13.2 Products offered 546
13.1.13.3 Recent developments 547
13.1.13.3.1 Product launches and approvals 547
13.1.13.3.2 Expansions 548
13.1.14 SEKISUI DIAGNOSTICS 549
13.1.14.1 Business overview 549
13.1.14.2 Products offered 549
13.1.15 BODITECH MED INC. 551
13.1.15.1 Business overview 551
13.1.15.2 Products offered 551
13.1.15.3 Recent developments 552
13.1.15.3.1 Product launches and approvals 552
13.1.15.3.2 Deals 552
13.1.15.3.3 Expansions 553
13.2 OTHER PLAYERS 554
13.2.1 GRIFOLS, S.A. 554
13.2.2 LIFESCAN IP HOLDINGS, LLC 555
13.2.3 PTS DIAGNOSTICS 556
13.2.4 EUROLYSER DIAGNOSTICA GMBH 557
13.2.5 RESPONSE BIOMEDICAL 558
13.2.6 ALFA SCIENTIFIC DESIGNS, INC. 559
13.2.7 BTNX INC. 560
13.2.8 ASCENSIA DIABETES CARE HOLDINGS AG 561
13.2.9 FLUXERGY 562
13.2.10 PRECISION BIOSENSOR, INC. 563
13.2.11 ACON LABORATORIES, INC. 564
13.2.12 MENARINI DIAGNOSTICS S.R.L 565
13.2.13 ORASURE TECHNOLOGIES, INC. 566
13.2.14 MANKIND PHARMA 567
14 APPENDIX 568
14.1 DISCUSSION GUIDE 568
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 574
14.3 CUSTOMIZATION OPTIONS 576
14.4 RELATED REPORTS 576
14.5 AUTHOR DETAILS 577

TABLE 1 POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS 51
TABLE 2 POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 59
TABLE 3 POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT 67
TABLE 4 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION,
2022 VS. 2035 VS. 2045 82
TABLE 5 GLOBAL DIABETES ESTIMATES (AGES 20-79) BY REGION,
2021 VS. 2030 VS. 2045 (IN THOUSANDS) 83
TABLE 6 PRODUCT WAIVERS, BY KEY PLAYER, 2021-2024 85
TABLE 7 AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022-2024 90
TABLE 8 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS,
BY KEY PLAYER, 2022-2024 91
TABLE 9 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022-2024 91
TABLE 10 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS,
BY REGION, 2022-2024 92
TABLE 11 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS,
BY REGION, 2022-2024 93
TABLE 12 POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 97
TABLE 13 POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2023 102
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION) 103
TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION) 103
TABLE 16 POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS,
2025-2026 104
TABLE 17 POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 105
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%) 107
TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY 108
TABLE 20 EUROPE: CLASSIFICATION OF IVD DEVICES 115
TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 117
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 118
TABLE 23 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES 120
TABLE 24 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 122
TABLE 25 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123
TABLE 26 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123
TABLE 28 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124
TABLE 29 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 127
TABLE 30 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON,
2021 VS. 2030 VS. 2045 (USD) 129
TABLE 31 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 129
TABLE 32 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 130
TABLE 33 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 34 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 35 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 36 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 37 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE 132
TABLE 38 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS,
BY REGION, 2022-2029 (USD MILLION) 132
TABLE 39 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 40 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 41 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 42 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 43 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE 134
TABLE 44 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022-2029 (USD MILLION) 135
TABLE 45 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 46 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 47 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 48 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION) 137
TABLE 49 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES
AVAILABLE WORLDWIDE 137
TABLE 50 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022-2029 (USD MILLION) 138
TABLE 51 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY,
2022-2029 (USD MILLION) 138
TABLE 52 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 53 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 54 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY,
2022-2029 (USD MILLION) 139
TABLE 55 KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE 140
TABLE 56 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 142
TABLE 57 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 142
TABLE 58 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 59 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 60 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 61 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 144
TABLE 62 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 145
TABLE 63 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 64 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 65 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 66 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 67 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 147
TABLE 68 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 147
TABLE 69 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 148
TABLE 70 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 148
TABLE 71 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 149
TABLE 72 POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 150
TABLE 73 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 74 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 75 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 151
TABLE 76 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 151
TABLE 77 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 152
TABLE 78 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 152
TABLE 79 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 80 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 81 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 82 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 83 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 154
TABLE 84 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 155
TABLE 85 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 155
TABLE 86 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 155
TABLE 87 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 88 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 89 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE 157
TABLE 90 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 158
TABLE 91 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 158
TABLE 92 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 158
TABLE 93 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 94 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 95 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 160
TABLE 96 POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 160
TABLE 97 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 98 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 99 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 100 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 101 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS
AVAILABLE WORLDWIDE 162
TABLE 102 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 163
TABLE 103 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 104 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 164
TABLE 105 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 164
TABLE 106 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 107 KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
AVAILABLE WORLDWIDE 166
TABLE 108 POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 166
TABLE 109 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 110 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 167
TABLE 111 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 167
TABLE 112 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 168
TABLE 113 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 169
TABLE 114 POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 169
TABLE 115 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 169
TABLE 116 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 117 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 118 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 119 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 172
TABLE 120 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 172
TABLE 121 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 173
TABLE 122 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 173
TABLE 123 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 173
TABLE 124 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 174
TABLE 125 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE 175
TABLE 126 POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 175
TABLE 127 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 128 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 129 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 130 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 131 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS,
BY TYPE, 2022-2029 (USD MILLION) 178
TABLE 132 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 178
TABLE 133 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 134 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 135 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 136 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 137 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE 181
TABLE 138 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 181
TABLE 139 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS
B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 140 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 182
TABLE 141 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 182
TABLE 142 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 143 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE 183
TABLE 144 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 184
TABLE 145 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 146 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 147 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 148 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 149 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE 186
TABLE 150 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 187
TABLE 151 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 187
TABLE 152 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 153 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 154 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 189
TABLE 155 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE 190
TABLE 156 POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 190
TABLE 157 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 158 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 159 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 160 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 161 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE 193
TABLE 162 POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 193
TABLE 163 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 193
TABLE 164 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 165 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 166 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 167 POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 196
TABLE 168 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 169 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 170 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 171 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 172 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE 198
TABLE 173 POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 198
TABLE 174 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 198
TABLE 175 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 176 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 177 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 178 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
AVAILABLE WORLDWIDE 200
TABLE 179 POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 201
TABLE 180 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 201
TABLE 181 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 182 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 183 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 202
TABLE 184 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 203
TABLE 185 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 203
TABLE 186 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 187 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 188 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 189 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 190 KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE 206
TABLE 191 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 206
TABLE 192 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 207
TABLE 193 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 194 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 195 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 196 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 197 POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 209
TABLE 198 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 209
TABLE 199 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 209
TABLE 200 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 210
TABLE 201 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 210
TABLE 202 POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 211
TABLE 203 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 204 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 205 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 206 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 207 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 208 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 213
TABLE 209 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 213
TABLE 210 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 214
TABLE 211 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 214
TABLE 212 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 215
TABLE 213 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE 216
TABLE 214 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 216
TABLE 215 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 216 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 217 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 218 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 218
TABLE 219 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE 218
TABLE 220 POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 219
TABLE 221 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 222 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 223 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 220
TABLE 224 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 220
TABLE 225 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045 221
TABLE 226 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE 222
TABLE 227 POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 222
TABLE 228 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 229 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 230 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 231 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 224
TABLE 232 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 225
TABLE 233 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY REGION, 2022-2029 (USD MILLION) 225
TABLE 234 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 226
TABLE 235 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 226
TABLE 236 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 226
TABLE 237 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 238 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE 227
TABLE 239 POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 228
TABLE 240 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 228
TABLE 241 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 242 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 243 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 230
TABLE 244 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE 231
TABLE 245 POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 231
TABLE 246 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 231
TABLE 247 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 232
TABLE 248 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 232
TABLE 249 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 233
TABLE 250 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE 233
TABLE 251 POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 234
TABLE 252 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 234
TABLE 253 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 235
TABLE 254 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 235
TABLE 255 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 236
TABLE 256 POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 237
TABLE 257 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 237
TABLE 258 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 238
TABLE 259 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 238
TABLE 260 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY,
2022-2029 (USD MILLION) 239
TABLE 261 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE 240
TABLE 262 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 240
TABLE 263 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 240
TABLE 264 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 265 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 266 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 242
TABLE 267 KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE 243
TABLE 268 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 243
TABLE 269 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 243
TABLE 270 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 271 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 272 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 245
TABLE 273 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 247
TABLE 274 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE 248
TABLE 275 POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 249
TABLE 276 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 249

TABLE 277 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 250
TABLE 278 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 250
TABLE 279 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 251
TABLE 280 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE 252
TABLE 281 POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION) 252
TABLE 282 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 253
TABLE 283 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY COUNTRY, 2022-2029 (USD MILLION) 253
TABLE 284 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 254
TABLE 285 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION) 254
TABLE 286 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 256
TABLE 287 KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS
AVAILABLE WORLDWIDE 257
TABLE 288 POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION,
2022-2029 (USD MILLION) 258
TABLE 289 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2022-2029 (USD MILLION) 258
TABLE 290 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2022-2029 (USD MILLION) 259
TABLE 291 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2022-2029 (USD MILLION) 259
TABLE 292 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2022-2029 (USD MILLION) 260
TABLE 293 KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS
AVAILABLE WORLDWIDE 261
TABLE 294 POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION,
2022-2029 (USD MILLION) 262
TABLE 295 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2029 (USD MILLION) 262
TABLE 296 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2029 (USD MILLION) 263
TABLE 297 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2029 (USD MILLION) 263
TABLE 298 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2029 (USD MILLION) 264
TABLE 299 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 265
TABLE 300 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY REGION, 2022-2029 (USD MILLION) 265
TABLE 301 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION) 265
TABLE 302 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION) 266
TABLE 303 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION) 266
TABLE 304 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION) 267
TABLE 305 KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE 267
TABLE 306 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022-2029 (USD MILLION) 268
TABLE 307 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION) 268
TABLE 308 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2022-2029 (USD MILLION) 269
TABLE 309 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2022-2029 (USD MILLION) 269
TABLE 310 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION) 270
TABLE 311 KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE 270
TABLE 312 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022-2029 (USD MILLION) 271
TABLE 313 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION) 271
TABLE 314 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2022-2029 (USD MILLION) 271
TABLE 315 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2022-2029 (USD MILLION) 272
TABLE 316 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION) 272
TABLE 317 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION) 274
TABLE 318 KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS
AVAILABLE WORLDWIDE 275
TABLE 319 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION,
2022-2029 (USD MILLION) 276
TABLE 320 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 276
TABLE 321 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 277
TABLE 322 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 277
TABLE 323 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 278
TABLE 324 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE 279
TABLE 325 POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022-2029 (USD MILLION) 279
TABLE 326 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION) 280
TABLE 327 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION) 280
TABLE 328 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION) 280
TABLE 329 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION) 281
TABLE 330 KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE 282
TABLE 331 POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION,
2022-2029 (USD MILLION) 283
TABLE 332 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 283
TABLE 333 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 284
TABLE 334 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 284
TABLE 335 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 285
TABLE 336 KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS
AVAILABLE WORLDWIDE 286
TABLE 337 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION,
2022-2029 (USD MILLION) 286
TABLE 338 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 287
TABLE 339 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 287
TABLE 340 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 288
TABLE 341 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 288
TABLE 342 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) 290
TABLE 343 POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND
SELF-TESTING, BY REGION, 2022-2029 (USD MILLION) 291
TABLE 344 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 291
TABLE 345 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 292
TABLE 346 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 292
TABLE 347 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 293
TABLE 348 POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 294
TABLE 349 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 294
TABLE 350 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022-2029 (USD MILLION) 295
TABLE 351 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 295
TABLE 352 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 296
TABLE 353 POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022-2029 (USD MILLION) 297
TABLE 354 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY,
2022-2029 (USD MILLION) 298
TABLE 355 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY,
2022-2029 (USD MILLION) 298
TABLE 356 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY,
2022-2029 (USD MILLION) 298
TABLE 357 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY,
2022-2029 (USD MILLION) 299
TABLE 358 POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022-2029 (USD MILLION) 300
TABLE 359 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION) 300
TABLE 360 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION) 300
TABLE 361 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION) 301
TABLE 362 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION) 301
TABLE 363 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) 302
TABLE 364 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 302
TABLE 365 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 303
TABLE 366 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 303
TABLE 367 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 304
TABLE 368 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) 306
TABLE 369 NORTH AMERICA: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET 309
TABLE 370 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 309
TABLE 371 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 310
TABLE 372 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 310
TABLE 373 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 311
TABLE 374 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 311
TABLE 375 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 312
TABLE 376 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE,
2022-2029 (USD MILLION) 312
TABLE 377 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 378 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 379 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 380 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 314
TABLE 381 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 314
TABLE 382 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 314
TABLE 383 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 315
TABLE 384 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 315
TABLE 385 NORTH AMERICA: NUMBER OF WOMEN USING HOME PREGNANCY KITS,
BY COUNTRY, 2022-2029 (MILLION UNIT) 315
TABLE 386 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 318
TABLE 387 US: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 318
TABLE 388 US: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 319
TABLE 389 US: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 319
TABLE 390 US: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 320
TABLE 391 US: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 320
TABLE 392 US: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 321
TABLE 393 US: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 321
TABLE 394 US: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 321
TABLE 395 US: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 322
TABLE 396 US: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 322
TABLE 397 US: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 322
TABLE 398 US: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 323
TABLE 399 US: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 323
TABLE 400 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 325
TABLE 401 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 325
TABLE 402 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 326
TABLE 403 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 326
TABLE 404 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 327
TABLE 405 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 327
TABLE 406 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 328
TABLE 407 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 328
TABLE 408 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 328
TABLE 409 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 329
TABLE 410 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 329
TABLE 411 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 329
TABLE 412 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 330
TABLE 413 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 330
TABLE 414 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
IN EUROPE 332
TABLE 415 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 332
TABLE 416 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 333
TABLE 417 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 333
TABLE 418 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 334
TABLE 419 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 334
TABLE 420 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 335
TABLE 421 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 335
TABLE 422 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 336
TABLE 423 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 336
TABLE 424 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 336
TABLE 425 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 337
TABLE 426 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 337
TABLE 427 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 337
TABLE 428 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 338
TABLE 429 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 338
TABLE 430 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 340
TABLE 431 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 341
TABLE 432 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 341
TABLE 433 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 342
TABLE 434 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 342
TABLE 435 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 436 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 437 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 438 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 344
TABLE 439 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 344
TABLE 440 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 344
TABLE 441 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 345
TABLE 442 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 345
TABLE 443 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 345
TABLE 444 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 347
TABLE 445 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 347
TABLE 446 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 348
TABLE 447 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 348
TABLE 448 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 349
TABLE 449 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 349
TABLE 450 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 350
TABLE 451 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 350
TABLE 452 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 350
TABLE 453 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 351
TABLE 454 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 351
TABLE 455 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 351
TABLE 456 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 352
TABLE 457 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 352
TABLE 458 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 354
TABLE 459 UK: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 354
TABLE 460 UK: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 355
TABLE 461 UK: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 355
TABLE 462 UK: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 356
TABLE 463 UK: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 356
TABLE 464 UK: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 357
TABLE 465 UK: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 357
TABLE 466 UK: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 357
TABLE 467 UK: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 358
TABLE 468 UK: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 358
TABLE 469 UK: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 358
TABLE 470 UK: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 359
TABLE 471 UK: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 359
TABLE 472 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 361
TABLE 473 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 361
TABLE 474 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 362
TABLE 475 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 362
TABLE 476 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 363
TABLE 477 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 363
TABLE 478 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 364
TABLE 479 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 364
TABLE 480 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 364
TABLE 481 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 365
TABLE 482 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 365
TABLE 483 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 365
TABLE 484 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 366
TABLE 485 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 366
TABLE 486 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 368
TABLE 487 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 368
TABLE 488 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 369
TABLE 489 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 369
TABLE 490 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 370
TABLE 491 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 370
TABLE 492 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 371
TABLE 493 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 371
TABLE 494 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 371
TABLE 495 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 372
TABLE 496 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 372
TABLE 497 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 372
TABLE 498 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 373
TABLE 499 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 373
TABLE 500 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 374
TABLE 501 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 375
TABLE 502 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 375
TABLE 503 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 376
TABLE 504 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 376
TABLE 505 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE,
2022-2029 (USD MILLION) 377
TABLE 506 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 377
TABLE 507 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 377
TABLE 508 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 378
TABLE 509 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 378
TABLE 510 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 378
TABLE 511 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 379
TABLE 512 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 379
TABLE 513 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 379
TABLE 514 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET 382
TABLE 515 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 382
TABLE 516 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 383
TABLE 517 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 383
TABLE 518 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 384
TABLE 519 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 384
TABLE 520 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 385
TABLE 521 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE,
2022-2029 (USD MILLION) 385
TABLE 522 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 386
TABLE 523 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 386
TABLE 524 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 386
TABLE 525 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 387
TABLE 526 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 387
TABLE 527 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION) 387
TABLE 528 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 388
TABLE 529 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 388
TABLE 530 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 390
TABLE 531 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 390
TABLE 532 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 391
TABLE 533 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 391
TABLE 534 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 392
TABLE 535 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 392
TABLE 536 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 393
TABLE 537 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 393
TABLE 538 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 393
TABLE 539 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 394
TABLE 540 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 394
TABLE 541 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 394
TABLE 542 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 395
TABLE 543 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 395
TABLE 544 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 397
TABLE 545 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 397
TABLE 546 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 398
TABLE 547 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 398
TABLE 548 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 399
TABLE 549 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 399
TABLE 550 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 400
TABLE 551 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 400
TABLE 552 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION) 400
TABLE 553 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2022-2029 (USD MILLION) 401
TABLE 554 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 401
TABLE 555 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2022-2029 (USD MILLION) 401
TABLE 556 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE,
2022-2029 (USD MILLION) 402
TABLE 557 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER,
2022-2029 (USD MILLION) 402